Surging Stocks: Aehr Test Systems, Synergy Pharmaceuticals, Great Basin Scientific, More

Helios and Matheson Analytics Continues to Rally in Wake of Merger Annoucement

Nano-cap Helios and Matheson Analytics Inc (NASDAQ:HMNY) has popped by more than 58% on robust volume after the company announced a pending merger with Zone Technologies yesterday, the creator of RedZone Maps. RedZone Maps is a real-time, GPS-driven crime and navigation map application and the two companies plan to leverage their artificial intelligence capabilities to enable RedZone Maps to further expand globally. The financial terms of the merger weren’t disclosed. Helios and Matheson Analytics Inc (NASDAQ:HMNY) wasn’t in the portfolios of any of the funds tracked by Insider Monkey at the end of the first quarter.

Aehr Test Systems Wins Order

Nano-cap Aehr Test Systems (NASDAQ:AEHR), a worldwide supplier of semiconductor test and burn-in equipment, is around 68% in the green after announcing that it received its first order for the company’s new FOX-XP production test cell. The order is worth over $4.5 million and $1.4 million of the order is payable immediately. The remainder is expected to paid through early calendar year 2017. CEO Gayn Erickson commented on the contract:

“We are very excited about this new customer for our FOX-XP multi-wafer burn-in and test system and to receive the first order for a full production test cell of this new product. The customer is one of the world’s largest semiconductor manufacturers and has selected the FOX-XP solution for a high-volume production application where extended burn-in is required to meet their stringent quality standards.”

Aehr Test Systems (NASDAQ:AEHR) was not held by any of the elite funds in our database as of March 31.

Synergy Rallies on Technicals and Value

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares have rallied by 9.11% today as traders snap up the stock in the hopes that the beaten-up biotech’s momentum will continue. Shares of the stock have surged past several moving averages and are up by more than 50% since mid-May. Synergy’s lead product candidate is plecanatide, which has a PDUFA date of January 29, 2017. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) was in 21 elite funds’ portfolios at the end of March.

Disclosure: None